Wits/SAMRC Antiviral Gene Therapy Research Unit (AGTRU)
Wits/SAMRC Antiviral Gene Therapy Research Unit (AGTRU)
Overview
We aim to counter viral infections that cause serious health problems in low- and middle-income countries (LMICs), particularly in sub-Saharan Africa.
Our research unit is dedicated to driving molecular technologies from discovery to clinical application, advancing innovation through intellectual property (IP) generation, and fostering the next generation of scientific leaders. With strong support from South African and international funding agencies, our research addresses critical challenges in biomedical science and healthcare in general.
We have a well-equipped molecular biology laboratory that specialises in a wide array of advanced methodologies.
Specific areas of expertise are in:
- Optimising mRNA production and lipid nanoparticle formulation for preclinical applications
- Engineering recombinant viral vectors for disease prevention and treatment
- Assessing gene transfer efficiency in mammalian cells
- Conducting preclinical evaluations of promising vaccines and antiviral therapeutics.
Mission
To build capacity in the research and development of mRNA and gene-based methods of preventing and treating infectious diseases. These diseases are relevant in low—and middle-income countries (LMICs), with hepatitis B, HIV, TB, SARS-CoV2, and Mpox being examples of targeted pathogens.
Vision
To advance the independence and development of vaccine production and gene therapy in low- and middle-income countries.